These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16357689)

  • 1. Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates.
    Miller RG; Chretien KC; Meoni LA; Liu YP; Klag MJ; Levine MA
    J Clin Rheumatol; 2005 Feb; 11(1):2-7. PubMed ID: 16357689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for osteoporosis in people with cystic fibrosis.
    Conwell LS; Chang AB
    Cochrane Database Syst Rev; 2012 Apr; (4):CD002010. PubMed ID: 22513903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate.
    Yavropoulou MP; Hamdy NA; Papapoulos SE
    Osteoporos Int; 2013 Aug; 24(8):2353-7. PubMed ID: 23436076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for osteoporosis in people with cystic fibrosis.
    Conwell LS; Chang AB
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD002010. PubMed ID: 24627308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
    Vis M; Bultink IE; Dijkmans BA; Lems WF
    Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
    Stokkers PC; Deley M; Van Der Spek M; Verberne HJ; Van Deventer SJ; Hommes DW
    Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous pamidronate in the treatment and prevention of osteoporosis.
    Chan SS; Nery LM; McElduff A; Wilmshurst EG; Fulcher GR; Robinson BG; Stiel JN; Gunton JE; Clifton-Bligh PB
    Intern Med J; 2004 Apr; 34(4):162-6. PubMed ID: 15086695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
    Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
    Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates.
    Eekman DA; Vis M; Bultink IE; Derikx HJ; Dijkmans BA; Lems WF
    BMC Musculoskelet Disord; 2009 Jul; 10():86. PubMed ID: 19604377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis.
    Heijckmann AC; Juttmann JR; Wolffenbuttel BH
    Neth J Med; 2002 Sep; 60(8):315-9. PubMed ID: 12481878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates for osteoporosis in people with cystic fibrosis.
    Brenckmann C; Papaioannou A
    Cochrane Database Syst Rev; 2001; (4):CD002010. PubMed ID: 11687132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.
    Cauza E; Etemad M; Winkler F; Hanusch-Enserer U; Partsch G; Noske H; Dunky A
    J Clin Pharm Ther; 2004 Oct; 29(5):431-6. PubMed ID: 15482386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance and effectiveness on pain control of Pamidronate® intravenous infusions in children with neuromuscular disorders.
    Wagner S; Poirot I; Vuillerot C; Berard C
    Ann Phys Rehabil Med; 2011 Sep; 54(6):348-58. PubMed ID: 21840280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and treatment costs of zoledronate versus pamidronate in paediatric osteoporosis.
    Saraff V; Sahota J; Crabtree N; Sakka S; Shaw NJ; Högler W
    Arch Dis Child; 2018 Jan; 103(1):92-94. PubMed ID: 28988216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.
    Reeves HL; Francis RM; Manas DM; Hudson M; Day CP
    Liver Transpl Surg; 1998 Sep; 4(5):404-9. PubMed ID: 9724478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass.
    Younes H; Farhat G; el-Hajj Fuleihan G
    J Clin Densitom; 2002; 5(2):143-9. PubMed ID: 12110757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.
    Krieg MA; Seydoux C; Sandini L; Goy JJ; Berguer DG; Thiébaud D; Burckhardt P
    Osteoporos Int; 2001; 12(2):112-6. PubMed ID: 11303710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis.
    Treeprasertsuk S; Silveira MG; Petz JL; Lindor KD
    Am J Ther; 2011 Sep; 18(5):375-81. PubMed ID: 20460985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.